The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
 
Paul G. Richardson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Novartis; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Michael Amatangelo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb
 
James R. Berenson
Employment - OncoTracker
Leadership - OncoTracker
Stock and Other Ownership Interests - OncoTracker
Honoraria - Bristol Myers Squibb Foundation; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Consulting or Advisory Role - Janssen; Sanofi
Speakers' Bureau - Bristol Myers Squibb Foundation; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Research Funding - Abbvie; Bristol Myers Squibb Foundation; Karyopharm Therapeutics; Novartis; Takeda
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb (Inst); Novartis (Inst); OncoTracker (Inst)
 
Claudio Cerchione
Honoraria - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
Consulting or Advisory Role - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi; SERVIER; Stemline Therapeutics; Takeda
Speakers' Bureau - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
 
Meletios A. Dimopoulos
Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
 
Charlotte Toftmann Hansen
No Relationships to Disclose
 
Soo Jeong Hwang
Employment - Bristol-Myers Squibb
 
Phillip Koo
Employment - Alexion Pharmaceuticals (I); Bristol-Myers Squibb; Novartis
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); Bristol-Myers Squibb; Novartis
 
Junya Kuroda
Consulting or Advisory Role - Asahi Kasei; Bristol Myers Squibb Foundation; Janssen; Pfizer
Speakers' Bureau - Bristol Myers Squibb Foundation; Janssen; Ono Pharmaceutical; Sanofi
Research Funding - Bristol Myers Squibb Foundation; Daiichi Sankyo; Eisai; Kyowa Kirin; Ono Pharmaceutical; Shionogi; Sumitomo Dainippon Pharma; Taiho Pharmaceutical
 
Albert Oriol
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; AstraZeneca; BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; IASO Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Meridian Therapeutics; Monte Rosa Therapeutics; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi; Takeda
Research Funding - Asylia Therapeutics, Inc. (Inst); BioTheryX (Inst); CARsgen Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Exelixis (Inst); Heidelberg Pharma (Inst); Janssen Biotech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.
 
HANG QUACH
Consulting or Advisory Role - Amgen; Antengene; Bristol-Myers Squibb/Celgene; Celgene; CSL Behring; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Pfizer; Roche; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
Marc S. Raab
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Takeda
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Pfizer; Sanofi; Takeda
 
Alberto Rocci
Employment - Bristol-Myers Squibb; Novartis (I)
Leadership - Owner of 100% stocks of Harlock Healthcare Consulting Ltd (UK privately-held company currently not active)
Stock and Other Ownership Interests - Novartis (I)
 
Yue Wang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Darrell White
Honoraria - Amgen; Antengene; Celgene/Bristol-Myers Squibb; Forus; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi
 
Brian Yu
Employment - Bristol-Myers Squibb
 
Zehua Zhou
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jessica Katz
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb